ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ublituximab

Also written as “Ublituximab”, “Cosibelimab + Ublituximab + Bendamustine combination” and “TGR-1202 + Ublituximab”.

Its studies are mostly in Multiple Sclerosis · Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, B-Cell · Schizophrenia · Myasthenia Gravis, led by 2 companies.

Drug pageUblituximab: every studyAll 37 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 20, 201423 company-led studies, 7 open or runningNext primary completion: Jan 21, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
TG Therapeutics227 open or runningphase 3since Nov 20, 2014Jul 17, 2012Jan 21, 2027phase 3 · NCT05877963
Laboratoire français de Fractionnement et de Biotechnologiesits history only10 open or runningphase 1since Mar 31, 2010Mar 31, 2010none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of TG Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Jul 17, 2012.

  1. Nov 18, 2015Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT02612311 · 603 enrolled · United States, Israel, Italy and more
  2. Jan 13, 2016Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT02656303 · 116 enrolled · United States, Italy, Poland and more
  3. Apr 10, 2016Phase 2 study in Multiple SclerosisNCT02738775 · 49 enrolled · United States
  4. Jun 28, 2017Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT03207256 · 51 enrolled · United States
  5. Sep 7, 20172 phase 3 studies in Relapsing Multiple Sclerosis (RMS)NCT03277261, NCT03277248
  6. Dec 18, 2017Phase 2 study in Multiple Sclerosis, Relapsing-RemittingNCT03381170 · 48 enrolled · United States
  7. Dec 11, 2018Phase 1 study in Lymphoma, B-CellNCT03778073 · 18 enrolled · United States
  8. Jan 9, 2019Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT03801525 · 277 enrolled · United States
  9. Jan 31, 2019Phase 2 study in Lymphoma, FollicularNCT03828448 · 34 enrolled · United States
  10. Oct 16, 2019Phase 3 study in Relapsing Multiple Sclerosis (RMS)NCT04130997 · 1,100 enrolled · United States, Belarus, Croatia and more
  11. May 18, 2023Phase 3 study in Relapsing Multiple SclerosisNCT05877963 · 800 planned · United States, Poland
  12. Oct 1, 20252 phase 3 studies in Relapsing Multiple SclerosisNCT07211633, NCT07220252
  13. Mar 9, 2026Phase 2 study in Multiple SclerosisNCT07503873 · 350 planned · Bosnia and Herzegovina, Georgia, North Macedonia and more
  14. Jun 10, 20262 phase 2 studiesNCT07673744, NCT07680946

Ahead

  1. Jan 21, 2027Primary completion: phase 3 study in Relapsing Multiple SclerosisNCT05877963
  2. Jul 31, 2027Primary completion: phase 2 study in Multiple SclerosisNCT07503873
  3. Jul 1, 2028Primary completion: phase 2 study in Myasthenia GravisNCT07673744
  4. Dec 12, 2028Primary completion: phase 2 study in SchizophreniaNCT07680946

TargetBeta

MS4A1 →read by rule
“A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 ”NCIt, by rule
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule

Other programs on MS4A1

ProgramCompanyFurthest phaseStudies
RituximabruleHoffmann-La Rochephase 4175
ocrelizumabruleHoffmann-La Rochephase 442
obinutuzumabruleHoffmann-La Rochephase 442
mosunetuzumabruleHoffmann-La Rochephase 314
glofitamabruleHoffmann-La Rochephase 313
epcoritamabruleGenmabphase 313
Anti-CD20 Monoclonal Antibody MIL62rulebeijing-mabworks-biotech-co-ltdphase 310
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
zuberitamabrulebioray-pharmaceutical-co-ltdphase 33
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28

Studies

All 22 TG Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07680946Schizophrenia · United States2RecruitingDec 12, 202860
NCT07673744Myasthenia Gravis · United States2RecruitingJul 1, 2028120
NCT07503873Multiple Sclerosis · Bosnia and Herzegovina, Georgia, North Macedonia and more2RecruitingJul 31, 2027350
NCT07220252Relapsing Multiple Sclerosis · United States, Poland, Slovakia3RecruitingJan 1, 2030240
NCT07211633Relapsing Multiple Sclerosis · Bosnia and Herzegovina, Bulgaria, Croatia and more3Active, not recruitingOct 31, 2026360
NCT05877963Relapsing Multiple Sclerosis · United States, Poland3RecruitingJan 21, 2027800
NCT04130997Relapsing Multiple Sclerosis (RMS) · United States, Belarus, Croatia and more3Active, not recruitingMay 31, 20321,100
NCT03828448Lymphoma, Follicular · United States2TerminatedMay 16, 202234
NCT03801525Leukemia, Lymphocytic, Chronic, B-Cell · United States3TerminatedDec 20, 2022277
NCT03778073Lymphoma, B-Cell · United States1TerminatedMay 3, 202218
NCT03381170Multiple Sclerosis, Relapsing-Remitting · United States2CompletedNov 11, 202248
NCT03277261Relapsing Multiple Sclerosis (RMS) · United States3CompletedJul 23, 2020549
NCT03277248Relapsing Multiple Sclerosis (RMS) · United States3CompletedAug 4, 2020545
NCT03207256Leukemia, Lymphocytic, Chronic, B-Cell · United States2TerminatedMay 25, 202251
NCT02738775Multiple Sclerosis · United States2CompletedSep 27, 201749
NCT02656303Leukemia, Lymphocytic, Chronic, B-Cell · United States, Italy, Poland and more2TerminatedMay 26, 2022116
NCT02612311Leukemia, Lymphocytic, Chronic, B-Cell · United States, Israel, Italy and more3TerminatedFeb 22, 2023603
NCT02301156Leukemia, Lymphocytic, Chronic, B-Cell · United States, Israel3CompletedApr 1, 2020126
NCT02013128Leukemia, Lymphocytic, Chronic, B-Cell · United States2CompletedDec 201566
NCT02006485Leukemia, Lymphocytic, Chronic, B-Cell · United States1CompletedOct 2019160
NCT01744912Lymphoma, Non-Hodgkin · United States1TerminatedFeb 7, 201410
NCT01647971Lymphoma, Non-Hodgkin · United States2CompletedMay 201539

How it is read

Names in the registry

  • “Ublituximab”, 21 entries
  • “Cosibelimab + Ublituximab + Bendamustine combination”, 2 entries
  • “TGR-1202 + Ublituximab”, 1 entry
  • “Ublituximab + TGR-1202”, 1 entry
  • “Ublituximab + TGR-1202 + ibrutinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.